7210 Wareham Drive, Tampa, FL 33647
May 22, 2024 A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association. The study was conducted by Blue Health Intelligence and is based on national pharmacy and medical claims data from […]
Most weight loss drug users quit before seeing benefits Read More »
May 20, 2024 Medifast today announced the launch of the first phase of its multimillion-dollar national marketing campaign. The campaign will highlight OPTAVIA’s new offering in collaboration with LifeMD®, the GLP-1 Lifestyle Program. View the full release here: https://www.businesswire.com/news/home/20240520770526/en/ This will be an investment of up to $30 million in company-led marketing efforts. Medifast is committed
Medifast To Launch National Marketing Campaign Read More »
Jan. 11, 2024 The pandemic had significant effects on the way commercial weight loss companies operate, along with the explosive demand for GLP-1 obesity drugs such as Ozempic, Wegovy, and Mounjaro. Marketdata estimates that between Medifast, Weight Watchers, Jenny Craig, and Noom, at least 26,500 weight loss coaches have lost their jobs since 2020. Here’s
Ozempic Boom Is Hurting Weight Loss Coaches Read More »
Nov. 8, 2019 “Our focus on long-term, sustainable growth at Medifast continued during the third quarter as we achieved record revenues, rapid year over year growth in the number of active earning coaches and solid growth in gross profits and net income,” said Dan Chard, Chief Executive Officer of Medifast.” Chard continued, “Growth at the rapid
Medifast Reports Q3 Results Read More »
Nov. 7, 2018 — 3rd Quarter 2018 Highlights: Revenue of $139.2 million, an increase of 80.3% year-over-year Active earning Coaches of 22,600, an increase of 59.2% year-over-year Net income of $13.8 million, an increase of 106.1% year-over-year Earnings per diluted share (“EPS”) of $1.14, an increase of 107.3% year-over-year Dan Chard, Medifast’s CEO, said: …”We are
Medifast Reports Q3 Results – Stock Gets Crushed Read More »